Nancy E. Denyes
2021
In 2021, Nancy E. Denyes earned a total compensation of $891.3K as General Counsel at aTYR PHARMA, a 43% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $165,876 |
|---|---|
| Option Awards | $353,702 |
| Salary | $360,577 |
| Other | $11,133 |
| Total | $891,288 |
Denyes received $360.6K in salary, accounting for 40% of the total pay in 2021.
Denyes also received $165.9K in non-equity incentive plan, $353.7K in option awards and $11.1K in other compensation.
Rankings
In 2021, Nancy E. Denyes' compensation ranked 9,147th out of 12,415 executives tracked by ExecPay. In other words, Denyes earned more than 26.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,147 out of 12,415 | 26th |
Division Manufacturing | 4,056 out of 5,508 | 26th |
Major group Chemicals And Allied Products | 1,787 out of 2,378 | 25th |
Industry group Drugs | 1,589 out of 2,099 | 24th |
Industry Biological Products, Except Diagnostic Substances | 347 out of 449 | 23rd |
Source: SEC filing on March 22, 2022.
Denyes' colleagues
We found two more compensation records of executives who worked with Nancy E. Denyes at aTYR PHARMA in 2021.